The preclinical data published in the American Journal of Transplantation will be presented in the form of a poster at the Cutting Edge of Transplantation (CEoT) Summit held in Scottsdale, Arizona, ...

Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) have announced a partnership to expand access to precision oncology, particularly for patients in low- and middle-income ...

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary ...

Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. For half a century, Helsinn has been operating with integrity, passion, and ...

Unlike traditional systemic vaccines, the mRNA vaccine under evaluation is designed to trigger a robust immune response directly at the site of influenza entry, with potential to reduce viral ...

COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year ...

Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.

An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching respiratory support supplement options New York, NY, ...

Clinical Claims: According to publicly available disclosures on the company's website, Ivím Health states that its patients lost an average of 46% more weight over 68 weeks compared to another ...

Bicara intends to use the net proceeds of the offering to further invest in and build its medical and commercial infrastructure to support a planned regulatory filing and commercial launch for ...

In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. ET on Thursday, March 12, 2026. The live audio webcast will be accessible on the Company ...

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...